StockNews.AI
FGEN
StockNews.AI
169 days

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

1. FibroGen will announce Q4 and full year 2024 results on March 17. 2. A conference call follows the earnings report to discuss performance. 3. Roxadustat is approved in several regions for CKD-induced anemia treatment. 4. The company is planning studies for Roxadustat in lower-risk MDS in the U.S. 5. FibroGen is developing FG-3246 for metastatic castration-resistant prostate cancer.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive anticipation ahead of earnings could lead to stock price increase. History shows price spikes prior to earnings announcements.

How important is it?

Expectations for financial results could positively impact investor sentiment.

Why Short Term?

The earnings announcement and conference call will have immediate market implications.

Related Companies

AMGNBMYJNJ
March 03, 2025 16:45 ET  | Source: FibroGen, Inc. SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website. About FibroGen  FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. For Investor Inquiries:David DeLucia, CFASenior Vice President and Chief Financial Officerir@fibrogen.com   

Related News